During the last session, Immunic Inc (NASDAQ:IMUX)’s traded shares were 0.62 million, with the beta value of the company hitting 1.88. At the end of the trading day, the stock’s price was $1.19, reflecting an intraday loss of -1.65% or -$0.02. The 52-week high for the IMUX share is $2.11, that puts it down -77.31 from that peak though still a striking 20.17% gain since the share price plummeted to a 52-week low of $0.95. The company’s market capitalization is $107.20M, and the average intraday trading volume over the past 10 days was 1.79 million shares, and the average trade volume was 622.45K shares over the past three months.

Immunic Inc (IMUX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. IMUX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.22.

Immunic Inc (NASDAQ:IMUX) trade information

Immunic Inc (IMUX) registered a -1.65% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.65% in intraday trading to $1.19, hitting a weekly high. The stock’s 5-day price performance is -14.39%, and it has moved by -25.16% in 30 days. Based on these gigs, the overall price performance for the year is 14.42%. The short interest in Immunic Inc (NASDAQ:IMUX) is 3.47 million shares and it means that shorts have 5.76 day(s) to cover.

The consensus price target of analysts on Wall Street is $5, which implies an increase of 76.2% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $5 respectively. As a result, IMUX is trading at a discount of -320.17% off the target high and -320.17% off the low.

Immunic Inc (IMUX) estimates and forecasts

Statistics show that Immunic Inc has outperformed its competitors in share price, compared to the industry in which it operates. Immunic Inc (IMUX) shares have gone down -13.14% during the last six months, with a year-to-date growth rate more than the industry average at 54.50% against 17.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 56.90% this quarter and then jump 56.30% in the quarter after that.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 10k as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 10k by the end of current fiscal year.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 31.12%. While earnings are projected to return 56.87% in 2024, the next five years will return 15.50% per annum.

IMUX Dividends

Immunic Inc is due to release its next quarterly earnings on 2024-Nov-07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Immunic Inc (NASDAQ:IMUX)’s Major holders

Immunic Inc insiders own 3.34% of total outstanding shares while institutional holders control 62.50%, with the float percentage being 64.66%. BVF INC/IL is the largest shareholder of the company, while 70.0 institutions own stock in it. As of 2024-06-30, the company held over 8.9 million shares (or 9.15% of all shares), a total value of $9.88 million in shares.

The next largest institutional holding, with 8.9 million shares, is of AVIDITY PARTNERS MANAGEMENT LP’s that is approximately 9.15% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $9.88 million.